Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

3.043 -0.167 (-5.20%)
Streaming Delayed Price Updated: 10:12 AM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116,382
Open 3.220
Bid (Size) 3.040 (5)
Ask (Size) 3.050 (5)
Prev. Close 3.210
Today's Range 3.025 - 3.230
52wk Range 2.120 - 5.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week. 
Via Talk Markets
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga

Performance

YTD
+22.21%
+22.21%
1 Month
+21.72%
+21.72%
3 Month
-29.39%
-29.39%
6 Month
-18.20%
-18.20%
1 Year
+14.40%
+14.40%

More News

Read More
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex
Via Talk Markets
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
Preview: Mind Medicine's Earnings
Via Benzinga
Analyst Expectations for Mind Medicine's Future
Via Benzinga
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
Via Talk Markets
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
Via Talk Markets
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
Via Benzinga
Topics Economy
Exposures Interest Rates
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22%
Via Talk Markets
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
Via Benzinga
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
From Mind Medicine
Via Business Wire
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
From Mind Medicine Inc.
Via Business Wire
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Via Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Via Benzinga
Exposures Product Safety
Psychedelic-Compound-Based Drug Stocks Continue To Fall
Via Talk Markets
3 Pharma Stocks to Dump Before the Damage Is Done
Via InvestorPlace
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
Via Benzinga
Major Psychedelic Drug Stocks Continued To Decline This Week
Via Talk Markets
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
From Mind Medicine Inc
Via Business Wire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.